Allogeneic and Autologous Anti-CD7 CAR-T Cell Therapies in Relapsed or Refractory T Cell Malignancies

被引：2
|
作者：
Zhang, Yinqiang [1 ,2 ]
Li, Chenggong [1 ,2 ]
Jiang, Huiwen [1 ,2 ]
Luo, Wenjing [1 ,2 ]
Du, Mengyi [1 ,2 ]
Zhou, Fen [1 ,3 ]
Tang, Lu [1 ,2 ]
Wu, Jianghua [1 ,2 ]
Wei, Qiuzhe [1 ,2 ]
Lu, Cong [1 ,2 ]
Kou, Haiming [1 ,2 ]
Wu, Di [4 ]
Alex, Chang H. [5 ]
Mei, Heng [1 ,2 ]
Hu, Yu [1 ,2 ]
机构：
[1] Hubei Clin Med Ctr Cell Therapy Neoplast Dis, Wuhan, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Inst Hematol, Wuhan, Peoples R China
[3] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pediat, Wuhan, Peoples R China
[4] Beijing GoBrd Hosp Management Co Ltd, Beijing, Peoples R China
[5] Shanghai YaKe Biotechnol Ltd, Shanghai, Peoples R China
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-170819
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4592 / 4594
页数：3
相关论文
共 50 条
  • [31] T cell senescence and CAR-T cell exhaustion in hematological malignancies
    Dimitri Kasakovski
    Ling Xu
    Yangqiu Li
    Journal of Hematology & Oncology, 11
  • [32] A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies
    Lu, Tangying Lily
    Pugach, Omar
    Somerville, Robert
    Rosenberg, Steven A.
    Kochendefer, James N.
    Better, Marc
    Feldman, Steven A.
    HUMAN GENE THERAPY METHODS, 2016, 27 (06) : 209 - 218
  • [33] Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy
    Chen, Wei
    Ma, Yuhan
    Shen, Ziyuan
    Chen, Huimin
    Ma, Ruixue
    Yan, Dongmei
    Shi, Ming
    Wang, Xiangmin
    Song, Xuguang
    Sun, Cai
    Cao, Jiang
    Cheng, Hai
    Zhu, Feng
    Sun, Haiying
    Li, Depeng
    Li, Zhenyu
    Zheng, Junnian
    Xu, Kailin
    Sang, Wei
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [34] CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies
    Li, Shiqi
    Wang, Xinxin
    Liu, Lin
    Liu, Jia
    Rao, Jun
    Yuan, Zhongtao
    Gao, Li
    Li, Yu
    Luo, Le
    Li, Gui
    Li, Zhimin
    Li, Sheng
    He, Jiaping
    Zhang, Lihua
    Chen, Lvzhe
    Huang, Wenhui
    Yin, Ping
    Li, Chunmin
    Li, Xiaoping
    Wang, Youcheng
    Dong, Yancheng
    Zhang, Dingsong
    Zang, Qingying
    Chen, Yingnian
    Shen, Lianjun
    Li, Wenling
    Cao, Wei
    Zhang, Xi
    Wang, Sanbin
    LEUKEMIA, 2023, 37 (11) : 2176 - 2186
  • [35] CD7 targeted “off-the-shelf” CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies
    Shiqi Li
    Xinxin Wang
    Lin Liu
    Jia Liu
    Jun Rao
    Zhongtao Yuan
    Li Gao
    Yu Li
    Le Luo
    Gui Li
    Zhimin Li
    Sheng Li
    Jiaping He
    Lihua Zhang
    Lvzhe Chen
    Wenhui Huang
    Ping Yin
    Chunmin Li
    Xiaoping Li
    Youcheng Wang
    Yancheng Dong
    Dingsong Zhang
    Qingying Zang
    Yingnian Chen
    Lianjun Shen
    Wenling Li
    Wei Cao
    Xi Zhang
    Sanbin Wang
    Leukemia, 2023, 37 : 2176 - 2186
  • [36] Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
    Christopher T. Su
    J. Christine Ye
    Journal of Hematology & Oncology, 14
  • [37] Autologous CD7-targeted CAR T-cell therapy for refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma.
    Zhao, Liping
    Pan, Jing
    Tang, Kaiting
    Tan, Yue
    Deng, Biping
    Ling, Zhuojun
    Song, Weiliang
    Chang, Alex H.
    Feng, Xiaoming
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
    Su, Christopher T.
    Ye, J. Christine
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [39] Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting
    Kang, Yun
    Li, Chenggong
    Mei, Heng
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [40] Feasibility of point-of-care manufactured anti-CD19 CAR-T cells (SiCF-019) for relapsed/refractory B cell malignancies
    Luanpitpong, Sudjit
    Klaihmon, Phatchanat
    Janan, Montira
    Kungwankiattichai, Smith
    Owattanapanich, Weerapat
    Issaragrisil, Surapol
    CANCER SCIENCE, 2025, 116 : 1213 - 1213
12345